Advanced prostate cancer risk in relation to toenail selenium levels

Journal of the National Cancer Institute

Volumn 105, Issue 18, 2013, Pages 1394-1401

  Geybels, Milan S ^a   Verhage, Bas A J ^a   Van Schooten, Frederik J ^b   Goldbohm, R Alexandra ^c   Van Den Brandt, Piet A ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c TNO   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

SELENIUM;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER RISK; CANCER STAGING; COHORT ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; NAIL; PRIORITY JOURNAL; PROSTATE CANCER; QUESTIONNAIRE; TOE NAIL;

AGED; ANTIOXIDANTS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NAILS; NEOPLASM STAGING; NETHERLANDS; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; QUESTIONNAIRES; RISK ASSESSMENT; RISK FACTORS; SELENIUM; TRACE ELEMENTS;

EID: 84886923853     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djt186     Document Type: Article

References (40)

1. Papp LV, Lu J, Holmgren A, et al. From selenium to selenoproteins: synthesis, identity, and their role in human health. Antioxid Redox Signal. 2007;9(7): 775-806.
2. Peters U, Takata Y. Selenium and the prevention of prostate and colorectal cancer. Mol Nutr Food Res. 2008;52(11): 1261-1272.
3. Rayman MP. The importance of selenium to human health. Lancet. 2000;356(9225): 233-241.
4. Rayman MP. Selenium and human health. Lancet. 2012;379(9822): 1256-1268.
5. Park K, Rimm E, Siscovick D, et al. Demographic and lifestyle factors and selenium levels in men and women in the U.S. Nutr Res Pract. 2011;5(4): 357-364.
6. Hurst R, Hooper L, Norat T, et al. Selenium and prostate cancer: systematic review and meta-analysis. Am J Clin Nutr. 2012;96(1): 111-122.
7. Slotnick MJ, Nriagu JO. Validity of human nails as a biomarker of arsenic and selenium exposure: a review. Environ Res. 2006;102(1): 125-139.
8. van den Brandt PA, Zeegers MP, Bode P, et al. Toenail selenium levels and the subsequent risk of prostate cancer: a prospective cohort study. Cancer Epidemiol Biomarkers Prev. 2003;12(9): 866-871.
9. Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2009;301(1): 39-51.
10. Klein EA, Thompson IM Jr, Tangen CM, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011;306(14): 1549-1556.
11. Dunn BK, Richmond ES, Minasian LM, et al. A nutrient approach to prostate cancer prevention: The Selenium and Vitamin E Cancer Prevention Trial (SELECT). Nutr Cancer. 2010;62(7): 896-918.
12. Schrauzer GN. RE: Lessons from the selenium and vitamin E cancer prevention trial (SELECT). Crit Rev Biotechnol. 2009;29(2): 81.
13. Duffield-Lillico AJ, Reid ME, Turnbull BW, et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiol Biomarkers Prev. 2002;11(7): 630-639.
14. Duffield-Lillico AJ, Dalkin BL, Reid ME, et al. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU Int. 2003;91(7): 608-612.
15. van den Brandt PA, Goldbohm RA, Van't Veer P, et al. A large-scale prospective cohort study on diet and cancer in The Netherlands. J Clin Epidemiol. 1990;43(3): 285-295.
16. van den Brandt PA, Schouten LJ, Goldbohm RA, et al. Development of a record linkage protocol for use in the Dutch Cancer Registry for epidemiological research. Int J Epidemiol. 1990;19(3): 553-558.
17. Goldbohm RA, van den Brandt PA, Dorant E. Estimation of the coverage of Dutch municipalities by cancer registries and PALGA based on hospital discharge data. Tijdschr Soc Gezondheidsz. 1994;19(3): 80-84.
18. Barlow WE, Ichikawa L, Rosner D, et al. Analysis of case-cohort designs. J Clin Epidemiol. 1999;52(12): 1165-1172.
19. Goldbohm RA, van den Brandt PA, Brants HA, et al. Validation of a dietary questionnaire used in a large-scale prospective cohort study on diet and cancer. Eur J Clin Nutr. 1994;48(4): 253-265.
20. Goldbohm RA, Van't Veer P, van den Brandt PA, et al. Reproducibility of a food frequency questionnaire and stability of dietary habits determined from five annually repeated measurements. Eur J Clin Nutr. 1995;49(6): 420-429.
21. Sobin L, Gospodarowicz M, Wittekind C, et al. TNM Classification of Malignant Tumors. 7th ed. Oxford: Wiley-Blackwell; 2009.
22. van den Brandt PA, Goldbohm RA, Van't Veer P, et al. A prospective cohort study on toenail selenium levels and risk of gastrointestinal cancer. J Natl Cancer Inst. 1993;85(3): 224-229.
23. van den Brandt PA, Goldbohm RA, Van't Veer P, et al. Predictors of toenail selenium levels in men and women. Cancer Epidemiol Biomarkers Prev. 1993;2(2): 107-112.
24. Steevens J, van den Brandt PA, Goldbohm RA, et al. Selenium status and the risk of esophageal and gastric cancer subtypes: the Netherlands cohort study. Gastroenterology. 2010;138(5): 1704-1713.
25. Zeegers MP, Goldbohm RA, Bode P, et al. Prediagnostic toenail selenium and risk of bladder cancer. Cancer Epidemiol Biomarkers Prev. 2002;11(11): 1292-1297.
26. Lin DY, Wei LY. The robust inference for the Cox proportional hazards model. J Am Stat Assoc. 1989;84(408): 1074-1078.
27. Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81(3): 515-526.
28. Geybels MS, Verhage BA, van Schooten FJ, et al. Measures of combined antioxidant and pro-oxidant exposures and risk of overall and advanced stage prostate cancer. Ann Epidemiol. 2012;22(11): 814-820.
29. Helzlsouer KJ, Huang HY, Alberg AJ, et al. Association between alphatocopherol, gamma-tocopherol, selenium, and subsequent prostate cancer. J Natl Cancer Inst. 2000;92(24): 2018-2023.
30. Yoshizawa K, Willett WC, Morris SJ, et al. Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer. J Natl Cancer Inst. 1998;90(16): 1219-1224.
31. Waters DJ, Shen S, Glickman LT, et al. Prostate cancer risk and DNA damage: translational significance of selenium supplementation in a canine model. Carcinogenesis. 2005;26(7): 1256-1262.
32. Allen NE, Appleby PN, Roddam AW, et al. Plasma selenium concentration and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition (EPIC). Am J Clin Nutr. 2008;88(6): 1567-1575.
33. Kok FJ, Hofman A, Witteman JC, et al. Decreased selenium levels in acute myocardial infarction. JAMA. 1989;261(8): 1161-1164.
34. Bukkens SG, de Vos N, Kok FJ, et al. Selenium status and cardiovascular risk factors in healthy Dutch subjects. J Am Coll Nutr. 1990;9(2): 128-135.
35. Van't Veer P, van der Wielen RP, Kok FJ, et al. Selenium in diet, blood, and toenails in relation to breast cancer: a case-control study. Am J Epidemiol. 1990;131(6): 987-994.
36. Bratt O. Hereditary prostate cancer: clinical aspects. J Urol. 2002;168(3): 906-913.
37. Verhage BA, Kiemeney LA. Inherited predisposition to prostate cancer. Eur J Epidemiol. 2003;18(11): 1027-1036.
38. Nomura AM, Lee J, Stemmermann GN, et al. Serum selenium and subsequent risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2000;9(9): 883-887.
39. Vogt TM, Ziegler RG, Graubard BI, et al. Serum selenium and risk of prostate cancer in U.S. blacks and whites. Int J Cancer. 2003;103(5): 664-670.
40. Peters U, Foster CB, Chatterjee N, et al. Serum selenium and risk of prostate cancer-a nested case-control study. Am J Clin Nutr. 2007;85(1): 209-217.